INTRODUCTION
Sulfonylurea represents a wide class of drugs used in the treatment of diabetes mellitus, compared to other drugs of sulfonylurea class; Glipizide has shown to have less chances of hypoglycemic shock as an adverse effect. The incidence of hypoglycemic symptoms with glipizide GITS is low (≤3%) 1 .
Relatively high dose of Glipizide makes it a good candidate for formulating it as a Sustained release dosage form. Glipizide is a second generation sulphonylurea agent that is available in a Gastrointestinal Therapeutic System (GITS) extended-release formulation. Glipizide GITS provides more stable plasma drug concentrations than the immediate-release formulation and the once-daily regimen may optimize patient compliance. In patients with type 2 diabetes mellitus, glipizide GITS is at least as effective as the immediate-release formulation of glipizide in providing glycaemic control, and may have a greater effect on fasting plasma glucose levels. Any therapeutic advantage over other antidiabetic agent remains to be established, but in a preliminary report (n = 40) glipizide GITS provided better glycaemic control and produced less fasting insulinaemia than glibenclamide 1 . However from manufacturer point of view manufacturing gastrointestinal therapeutic system is comparatively more complicated process and requires more careful handling and control mechanism than formulating matrix tablets.
So manufacturing GITS is technically challenging for developing countries and it also results in increase cost of the tablets. Due to this reason matrix system tablet are required which require less technology and are cheaper compared to GITS 1 . Hydroxy propyl methyl cellulose is the methyl cellulose derivative used as binder in either wet or dry granulation. Depending upon the viscosity grades, concentration of 2-20% are used for film coating where as high viscosity grades may be used to retard the release of drugs from a matrix in tablets.
MATERIALS AND METHODS
Sustained release glipizide matrix tablets were prepared by wet granulation and compression as reported in previous report with some modification2. For these matrix systems, glipizide, lactose, HPMC (5 cps and 15 cps), PVPK 30, magnesium stearate and aerosil were weighed individually. Lactose, HPMC and PVPK 30 were passed through sieve size 20 and magnesium stearate and aerosil were passed through sieve size 60. The drug was suspended in methylene chloride (100 ml) and then mixed with lactose slowly for uniform adsorption of drug on lactose particles. It was dried for 1 hour in open air. The dried granules were passed through mesh no 20. These granules were mixed with HPMC and PVP K30 in polythene bag for 15 minutes and then magnesium stearate and aerosil were finally added. Then it was compressed adjusting final weight of tablet equal to 600 mg.
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Method of analysis
Standard preparation 100 mg of reference standard were weighed and dissolved in 100 ml of 0.1 NaOH to make the concentration of 1 mg/ml. Serial dilution was done to make the final concentration of 0.01mg/ml.
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Sample preparation 10 ml of the samples were withdrawn at the time interval of 0.5 hr, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 7 hr and 8 hr. The samples withdrawn were replaced by equal amount of dissolution medium.
Dissolution
The release of glipizide from sustained release formulation was studied using Elecrolab dissolution apparatus. 2 For each test, six formulation was placed in the flask containing 900 ml 0.1 M NaOH, dissolution medium 2 , at 37±2°C at 50 rpm 2 . Ten ml aliquot of the medium was sampled at pre-determined time of 8 hours. The sample was filtered and the concentration of glipizide was determined by measuring ultraviolet absorption at 276 nm 3 . The mean of six determinants was used to calculate drug release from each formulation. In the formulation F12-F17, PVP K30 was added and the amount used was 4% of total mass of each tablet. The amount of Magnesium Sterate and Colloidal Silicon dioxide (Aerosil) was fixed at 2% and 0.4% respectively for total weight of each tablet.
RESULTS AND DISCUSSIONS
The release percentage of the glipizide drug from the formulation was studied by changing the viscosity grade as well as the mass of the polymer in the tablet matrix. Friability, hardness and weight variation results are also compared with variation in polymers used. The compression pressure was adjusted in such a way that it passes the physical parameters. As the physical parameter was passed, then dissolution test was carried out for each formulation. Firstly, the dissolution test of the formulations containing 20%, 30% and 40% HPMC were carried out. The dissolution of these concentrations did not give the desired result showing the release percentage of 83% to 94% within half hour as shown in table 4. So the mass of HPMC was increased according to Handbook of Excipients which states that concentration of HPMC can be increased within the range of 20%-80%. The data shown in Table 5 suggests that increasing the concentration of HPMC within the range 60%-80%, the release rate of the glipizide is decreased but it did not meet the desired objective of our research. Table 2 shows that increasing the HPMC up to maximum limit caused the failure in result of friability and hardness. To improve the hardness of a tablet in a formulation containing higher concentration of HPMC, PVP K30 (Polyvinyl Pyrrolodine K 30) as binder was added. The fixed quantity of binder used in these formulations had shown the desirable effect as shown in Table 7 and 8. Similarly, the dissolution test of the marketed sample (Glynase SR) was also carried out as illustrated in Table 9 . The release percentage and pattern of the glipizide in marketed sample and F13 is nearly same. With the increase in mass of HPMC to 60%, 70% and 80% of total mass of formulation, the release percentage of glipizide is reduced. F8 and F9 had shown the release rate up to 5 hours. The advantage of such formulation is that it is cheaper and do not require expensive equipments for manufacture than other sustain release formulation of glipizide like osmotic pump dosage form.
